Literature DB >> 2665687

Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome.

E Shapiro1, A K Shapiro, G Fulop, M Hubbard, J Mandeli, J Nordlie, R A Phillips.   

Abstract

The results of this controlled study of the treatment of 57 patients with Gilles de la Tourette's syndrome suggested that both haloperidol and pimozide were more effective than placebo, but that haloperidol was slightly more effective than pimozide. Adverse effects occurred more frequently with haloperidol vs placebo than with pimozide vs placebo, but the frequency was not significantly different for haloperidol compared with pimozide. Clinically significant cardiac effects did not occur at a maximum dosage of 0.3 mg/kg or 20 mg/d for pimozide and 10 mg/d for haloperidol. However, the QTc interval was prolonged during pimozide treatment compared with that during haloperidol treatment, although the values for both medications were not in an abnormal range.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2665687     DOI: 10.1001/archpsyc.1989.01810080052006

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  57 in total

Review 1.  Typical neuroleptics in child and adolescent psychiatry.

Authors:  C Gillberg
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 2.  The significance of QT interval in drug development.

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 3.  Types of psychiatric treatment. Drug treatment.

Authors:  M Prendergast
Journal:  Arch Dis Child       Date:  1992-12       Impact factor: 3.791

Review 4.  An update on Tourette syndrome.

Authors:  Thomas E Kimber
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

Review 5.  The QT interval and psychotropic medications in children: recommendations for clinicians.

Authors:  Paul McNally; Fiona McNicholas; Paul Oslizlok
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-08-29       Impact factor: 4.785

Review 6.  Pimozide for tics in Tourette's syndrome.

Authors:  Tamara Pringsheim; Connie Marras
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

Review 7.  Emerging treatments for Tourette's disorder.

Authors:  Michael H Bloch
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

8.  Separable noradrenergic and dopaminergic regulation of prepulse inhibition in rats: implications for predictive validity and Tourette Syndrome.

Authors:  Neal R Swerdlow; Michele J Bongiovanni; Laura Tochen; Jody M Shoemaker
Journal:  Psychopharmacology (Berl)       Date:  2006-04-01       Impact factor: 4.530

Review 9.  Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents.

Authors:  Hannah Weisman; Imraan A Qureshi; James F Leckman; Lawrence Scahill; Michael H Bloch
Journal:  Neurosci Biobehav Rev       Date:  2012-10-23       Impact factor: 8.989

10.  Levetiracetam as an alternative therapy for Tourette syndrome.

Authors:  M A Martínez-Granero; A García-Pérez; F Montañes
Journal:  Neuropsychiatr Dis Treat       Date:  2010-06-24       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.